Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2026)

InMed Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.51 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 85.99% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$3.32, up 75.57%, while the annual FY2025 figure was -$8.36, 58.49% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.51 at InMed Pharmaceuticals, down from -$0.44 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.14 in Q2 2023 and troughed at -$15.24 in Q3 2023.
  • A 4-year average of -$3.51 and a median of -$3.14 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 2562.39% in 2024 and later skyrocketed 88.25% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$6.14 in 2022, then surged by 39.58% to -$3.71 in 2023, then rose by 1.89% to -$3.64 in 2024, then skyrocketed by 85.99% to -$0.51 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for INM at -$0.51 in Q4 2025, -$0.44 in Q3 2025, and -$0.43 in Q2 2025.